1
|
Vaidyanathan V, Naidu V, Kao CHJ, Karunasinghe N, Bishop KS, Wang A, Pallati R, Shepherd P, Masters J, Zhu S, Goudie M, Krishnan M, Jabed A, Marlow G, Narayanan A, Ferguson LR. Environmental factors and risk of aggressive prostate cancer among a population of New Zealand men - a genotypic approach. MOLECULAR BIOSYSTEMS 2017; 13:681-698. [PMID: 28252132 DOI: 10.1039/c6mb00873a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Prostate cancer is one of the most significant health concerns for men worldwide. Numerous researchers carrying out molecular diagnostics have indicated that genetic interactions with biological and behavioral factors play an important role in the overall risk and prognosis of this disease. Single nucleotide polymorphisms (SNPs) are increasingly becoming strong biomarker candidates to identify susceptibility to prostate cancer. We carried out a gene × environment interaction analysis linked to aggressive and non-aggressive prostate cancer (PCa) with a number of SNPs. By using this method, we identified the susceptible alleles in a New Zealand population, and examined the interaction with environmental factors. We have identified a number of SNPs that have risk associations both with and without environmental interaction. The results indicate that certain SNPs are associated with disease vulnerability based on behavioral factors. The list of genes with SNPs identified as being associated with the risk of PCa in a New Zealand population is provided in the graphical abstract.
Collapse
Affiliation(s)
- Venkatesh Vaidyanathan
- Discipline of Nutrition and Dietetics, FM & HS, University of Auckland, Auckland 1023, New Zealand. and Auckland Cancer Society Research Centre, Auckland 1023, New Zealand.
| | - Vijay Naidu
- School of Engineering, Computer and Mathematical Sciences, Auckland University of Technology, Auckland 1010, New Zealand.
| | - Chi Hsiu-Juei Kao
- Discipline of Nutrition and Dietetics, FM & HS, University of Auckland, Auckland 1023, New Zealand. and Auckland Cancer Society Research Centre, Auckland 1023, New Zealand.
| | | | - Karen S Bishop
- Auckland Cancer Society Research Centre, Auckland 1023, New Zealand.
| | - Alice Wang
- Discipline of Nutrition and Dietetics, FM & HS, University of Auckland, Auckland 1023, New Zealand. and Auckland Cancer Society Research Centre, Auckland 1023, New Zealand.
| | - Radha Pallati
- Discipline of Nutrition and Dietetics, FM & HS, University of Auckland, Auckland 1023, New Zealand.
| | - Phillip Shepherd
- Sequenom Facility, Liggins Institute, University of Auckland, Auckland 1023, New Zealand.
| | - Jonathan Masters
- Urology Department, Auckland District Health Board, Auckland, New Zealand.
| | - Shuotun Zhu
- Discipline of Nutrition and Dietetics, FM & HS, University of Auckland, Auckland 1023, New Zealand. and Auckland Cancer Society Research Centre, Auckland 1023, New Zealand.
| | - Megan Goudie
- Urology Department, Auckland District Health Board, Auckland, New Zealand.
| | - Mohanraj Krishnan
- Department of Obstetrics and Gynaecology, FMHS, University of Auckland, Auckland 1023, New Zealand.
| | - Anower Jabed
- Department of Molecular Medicine and Pathology, FM & HS, University of Auckland, Auckland 1023, New Zealand.
| | - Gareth Marlow
- Experimental Cancer Medicine Centre, Cardiff University, Cardiff, CF14 4XN, UK.
| | - Ajit Narayanan
- School of Engineering, Computer and Mathematical Sciences, Auckland University of Technology, Auckland 1010, New Zealand.
| | - Lynnette R Ferguson
- Discipline of Nutrition and Dietetics, FM & HS, University of Auckland, Auckland 1023, New Zealand. and Auckland Cancer Society Research Centre, Auckland 1023, New Zealand.
| |
Collapse
|
5
|
Amankwah EK, Kelemen LE, Wang Q, Song H, Chenevix-Trench G, Beesley J, Webb PM, Pearce CL, Wu AH, Pike MC, Stram DO, Chang-Claude J, Wang-Gohrke S, Ness RB, Goode EL, Cunningham JM, Fridley BL, Vierkant RA, Tworoger SS, Whittemore AS, McGuire V, Sieh W, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Rossing MA, Doherty JA, Goodman MT, Carney ME, Lurie G, Wilkens LR, Kjær SK, Høgdall E, Cramer DW, Terry KL, Garcia-Closas M, Yang H, Lissowska J, Anton-Culver H, Ziogas A, Schildkraut JM, Berchuck A, Pharoah PDP. Prostate cancer susceptibility polymorphism rs2660753 is not associated with invasive ovarian cancer. Cancer Epidemiol Biomarkers Prev 2011; 20:1028-31. [PMID: 21415361 DOI: 10.1158/1055-9965.epi-11-0053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
BACKGROUND We previously reported an association between rs2660753, a prostate cancer susceptibility polymorphism, and invasive epithelial ovarian cancer (EOC; OR = 1.2, 95% CI=1.0-1.4, P(trend) = 0.01) that showed a stronger association with the serous histological subtype (OR = 1.3, 95% CI = 1.1-1.5, P(trend) = 0.003). METHODS We sought to replicate this association in 12 other studies comprising 4,482 cases and 6,894 controls of white non-Hispanic ancestry in the Ovarian Cancer Association Consortium. RESULTS No evidence for an association with all cancers or serous cancers was observed in a combined analysis of data from the replication studies (all: OR = 1.0, 95% CI = 0.9-1.1, P(trend) = 0.61; serous: OR = 1.0, 95% CI = 0.9-1.1, P(trend) = 0.85) or from the combined analysis of discovery and replication studies (all: OR = 1.0, 95% CI = 1.0-1.1, P(trend) = 0.28; serous: OR = 1.1, 95% CI = 1.0-1.2, P(trend) = 0.11). There was no evidence for statistical heterogeneity in ORs across the studies. CONCLUSIONS Although rs2660753 is a strong prostate cancer susceptibility polymorphism, the association with another hormonally related cancer, invasive EOC, is not supported by this replication study. IMPACT Our findings, based on a larger sample size, emphasize the importance of replicating potentially promising genetic risk associations.
Collapse
Affiliation(s)
- Ernest K Amankwah
- Department of Population Health Research, Alberta Health Services-Cancer Care, Calgary, Canada
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Dürst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Gore ME, De Vivo I, Hillemanns P, Hogdall C, Hogdall E, Iversen ES, Jacobs IJ, Jakubowska A, Li D, Lissowska J, Lubiński J, Lurie G, McGuire V, McLaughlin J, Mędrek K, Moorman PG, Moysich K, Narod S, Phelan C, Pye C, Risch H, Runnebaum IB, Severi G, Southey M, Stram DO, Thiel FC, Terry KL, Tsai YY, Tworoger SS, Van Den Berg DJ, Vierkant RA, Wang-Gohrke S, Webb PM, Wilkens LR, Wu AH, Yang H, Brewster W, Ziogas A, Houlston R, Tomlinson I, Whittemore AS, Rossing MA, Ponder BA, Pearce CL, Ness RB, Menon U, Kjaer SK, Gronwald J, Garcia-Closas M, Fasching PA, Easton DF, Chenevix-Trench G, Berchuck A, Pharoah PD, Gayther SA. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 2009; 41:996-1000. [PMID: 19648919 PMCID: PMC2844110 DOI: 10.1038/ng.424] [Citation(s) in RCA: 255] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2009] [Accepted: 07/02/2009] [Indexed: 12/11/2022]
Abstract
Epithelial ovarian cancer has a major heritable component, but the known susceptibility genes explain less than half the excess familial risk. We performed a genome-wide association study (GWAS) to identify common ovarian cancer susceptibility alleles. We evaluated 507,094 SNPs genotyped in 1,817 cases and 2,353 controls from the UK and approximately 2 million imputed SNPs. We genotyped the 22,790 top ranked SNPs in 4,274 cases and 4,809 controls of European ancestry from Europe, USA and Australia. We identified 12 SNPs at 9p22 associated with disease risk (P < 10(-8)). The most significant SNP (rs3814113; P = 2.5 x 10(-17)) was genotyped in a further 2,670 ovarian cancer cases and 4,668 controls, confirming its association (combined data odds ratio (OR) = 0.82, 95% confidence interval (CI) 0.79-0.86, P(trend) = 5.1 x 10(-19)). The association differs by histological subtype, being strongest for serous ovarian cancers (OR 0.77, 95% CI 0.73-0.81, P(trend) = 4.1 x 10(-21)).
Collapse
Affiliation(s)
- Honglin Song
- CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
| | - Susan J. Ramus
- Department of Gynaecological Oncology, UCL EGA Institute for Women’s Health, University College London, UK
| | - Jonathan Tyrer
- CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
| | - Kelly L. Bolton
- CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
| | - Aleksandra Gentry-Maharaj
- Department of Gynaecological Oncology, UCL EGA Institute for Women’s Health, University College London, UK
| | - Eva Wozniak
- Department of Gynaecological Oncology, UCL EGA Institute for Women’s Health, University College London, UK
| | | | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
| | - Daniel W. Cramer
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, MA
| | - Richard DiCioccio
- Department of Cancer Genetics and the Gilda Radner Familial Ovarian Cancer Registry Buffalo, NY, USA
| | - Thilo Dörk
- Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany
| | | | - Marc T Goodman
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, USA
| | | | - Thomas Sellers
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
| | - Laura Baglietto
- Cancer Epidemiology Centre, The Cancer Council Victoria, Rathdowne Street, Carlton VIC 3053, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Swanston Street, Carlton VIC 3053, Australia
| | | | - Jonathan Beesley
- The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia
| | - Jan Blaakaer
- Department of Gynaecological and Obstetrics, Skejby University Hospital, Arhus
| | - Michael E Carney
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, USA
| | - Stephen Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
| | - Zhihua Chen
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
| | | | - Ed Dicks
- CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
| | - Jennifer A. Doherty
- Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Matthias Dürst
- Department of Gynaecology and Obstetrics, University Hospital of Jena, Germany
| | - Arif B. Ekici
- Institute of Human Genetics, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | | | | | - Graham Giles
- Cancer Epidemiology Centre, The Cancer Council Victoria, Rathdowne Street, Carlton VIC 3053, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Swanston Street, Carlton VIC 3053, Australia
| | - Martin E. Gore
- The Royal Marsden Hospital, Gynecological Oncology Unit, London, UK
| | - Immaculata De Vivo
- Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital & Harvard Medical School, Boston, MA
| | - Peter Hillemanns
- Clinics of Obstetrics and Gynaecology, Hannover Medical School, Hannover, Germany
| | - Claus Hogdall
- The Gyneacologic Clinic, The Juliane Marie Centre, Rigshospitalet, Copenhagen, Denmark
| | - Estrid Hogdall
- Department of Viruses, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
| | | | - Ian J Jacobs
- Department of Gynaecological Oncology, UCL EGA Institute for Women’s Health, University College London, UK
| | - Anna Jakubowska
- International Hereditary Cancer Center, Department Of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Dong Li
- Department of Epidemiology, University of California Irvine, USA
| | - Jolanta Lissowska
- Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Cancer Centre and Institute of Oncology, Warsaw, Poland
| | - Jan Lubiński
- International Hereditary Cancer Center, Department Of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Galina Lurie
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, USA
| | - Valerie McGuire
- Department of Health Research and Policy, Stanford University School of Medicine, Stanford, USA
| | - John McLaughlin
- Samuel Lunenfeld Research Institute, 60 Murray Street, Toronto, ON, Canada
| | - Krzysztof Mędrek
- International Hereditary Cancer Center, Department Of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Patricia G. Moorman
- The Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA
| | | | - Steven Narod
- Center for Research in Women’s Health, 790 Bay St., Toronto, ON, Canada
| | | | - Carole Pye
- CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
| | - Harvey Risch
- Yale University, 60 College Street, New Haven, CT, USA
| | - Ingo B Runnebaum
- Department of Gynaecology and Obstetrics, University Hospital of Jena, Germany
| | - Gianluca Severi
- Cancer Epidemiology Centre, The Cancer Council Victoria, Rathdowne Street, Carlton VIC 3053, Australia
- Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, University of Melbourne, Swanston Street, Carlton VIC 3053, Australia
| | - Melissa Southey
- Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, VIC 3010, Australia
| | - Daniel O. Stram
- University of Southern California, Keck School of Medicine, Los Angeles, California, USA
| | - Falk C. Thiel
- University Hospital Erlangen, Department of Gynecology and Obstetrics, Germany
| | - Kathryn L. Terry
- Obstetrics and Gynecology Epidemiology Center, Brigham and Women’s Hospital, Boston, MA
| | - Ya-Yu Tsai
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, USA
| | - Shelley S. Tworoger
- Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital & Harvard Medical School, Boston, MA
| | - David J. Van Den Berg
- University of Southern California, Keck School of Medicine, Los Angeles, California, USA
| | | | - Shan Wang-Gohrke
- Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany
| | - Penelope M. Webb
- The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia
| | - Lynne R. Wilkens
- Epidemiology Program, Cancer Research Center of Hawaii, University of Hawaii, USA
| | - Anna H Wu
- University of Southern California, Keck School of Medicine, Los Angeles, California, USA
| | - Hannah Yang
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
| | - Wendy Brewster
- Department of Obstetrics and Gynecology, University North Carolina, Chapel Hill, North Carolina, USA
| | - Argyrios Ziogas
- Department of Epidemiology, University of California Irvine, USA
| | | | | | | | - Richard Houlston
- Section of Cancer Genetics, Institute of Cancer Research, Sutton, UK
| | - Ian Tomlinson
- Population and Functional Genetics Lab, Wellcome Trust Centre for Human Genetics, Oxford, UK
| | - Alice S Whittemore
- Department of Health Research and Policy, Stanford University School of Medicine, Stanford, USA
| | - Mary Anne Rossing
- Program in Epidemiology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Bruce A.J. Ponder
- CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
| | - Celeste Leigh Pearce
- University of Southern California, Keck School of Medicine, Los Angeles, California, USA
| | - Roberta B. Ness
- The University of Texas, School of Public Health, Houston, TX, USA
| | - Usha Menon
- Department of Gynaecological Oncology, UCL EGA Institute for Women’s Health, University College London, UK
| | - Susanne Krüger Kjaer
- Department of Viruses, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark
| | - Jacek Gronwald
- International Hereditary Cancer Center, Department Of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - Montserrat Garcia-Closas
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
| | - Peter A. Fasching
- University Hospital Erlangen, Department of Gynecology and Obstetrics, Germany
- University of California at Los Angeles, David Geffen School of Medicine, Division of Hematology and Oncology
| | - Douglas F Easton
- CR-UK Genetic Epidemiology Unit, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
| | - Georgia Chenevix-Trench
- The Queensland Institute of Medical Research, Post Office Royal Brisbane Hospital, Australia
| | - Andrew Berchuck
- The Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, USA
| | - Paul D.P. Pharoah
- CR-UK Department of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, UK
| | - Simon A. Gayther
- Department of Gynaecological Oncology, UCL EGA Institute for Women’s Health, University College London, UK
| |
Collapse
|